Assignee
NANTCELL INC
US·41 granted patents·32 pending applications·27 citations·filing 2017–2025
Top patents by PatentIndex Score
73 records- 0197US11554167B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2022·Granted Jan 17, 2023·3 cites·9 claims
- 0296US12016911B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2023·Granted Jun 25, 2024·1 cites·20 claims
- 0396US11364291B1Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2020·Granted Jun 21, 2022·3 cites·14 claims
- 0495US11857612B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2022·Granted Jan 2, 2024·1 cites·17 claims
- 0592US12516093B2Recombinant erIL-15 NK cellsNANTCELL INC·Filed 2022·Granted Jan 6, 2026·1 cites·15 claims
- 0691US12156901B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2023·Granted Dec 3, 2024·1 cites·15 claims
- 0790US12168048B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2024·Granted Dec 17, 2024·0 cites·18 claims
- 0890US11229668B2Maximizing T-cell memory and compositions and methods thereforNANTCELL INC·Filed 2018·Granted Jan 25, 2022·3 cites·20 claims
- 0990US2025064911A1Bacillus calmette-guerin (bcg) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2024·Application pending·0 cites
- 1086US11701408B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2019·Granted Jul 18, 2023·2 cites·6 claims
- 1186US11311603B2HIV treatment compositions and methodsNANTCELL INC·Filed 2019·Granted Apr 26, 2022·2 cites·15 claims
- 1286US11154597B2Sequence arrangements and sequences for neoepitope presentationNANTCELL INC·Filed 2017·Granted Oct 26, 2021·2 cites·4 claims
- 1385US12303477B2HIV treatment compositions and methodsNANTCELL INC·Filed 2023·Granted May 20, 2025·0 cites·14 claims
- 1485US12285481B2Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid proteinNANTCELL INC·Filed 2023·Granted Apr 29, 2025·0 cites·12 claims
- 1584US12580056B2Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2024·Granted Mar 17, 2026·0 cites·20 claims
- 1684US12303552B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2024·Granted May 20, 2025·0 cites·18 claims
- 1784US11662938B2Object storage and access management systems and methodsNANTCELL INC·Filed 2021·Granted May 30, 2023·2 cites·20 claims
- 1883US12050802B2Object storage and access management systems and methodsNANTCELL INC·Filed 2023·Granted Jul 30, 2024·1 cites·22 claims
- 1983US11779637B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2018·Granted Oct 10, 2023·1 cites·10 claims
- 2083US11590217B2Neoepitope vaccine and immune stimulant combinations and methodsNANTCELL INC·Filed 2019·Granted Feb 28, 2023·1 cites·6 claims
- 2182US12427184B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2025·Granted Sep 30, 2025·0 cites·13 claims
- 2282US12112838B2Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2023·Granted Oct 8, 2024·0 cites·20 claims
- 2382US11894109B1Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2019·Granted Feb 6, 2024·2 cites·18 claims
- 2479US12311018B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2023·Granted May 27, 2025·0 cites·10 claims
- 2579US2025118436A1Deep Learning Models For Tumor EvaluationNANTCELL INC·Filed 2024·Application pending·0 cites
- 2677US12487241B2Rapid verification of virus particle production for a personalized vaccineNANTCELL INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2777US11786577B2HIV treatment compositions and methodsNANTCELL INC·Filed 2021·Granted Oct 17, 2023·0 cites·20 claims
- 2877US2025255840A1HIV Treatment Compositions And MethodsNANTCELL INC·Filed 2025·Application pending·0 cites
- 2976US12527865B2haNK cetuximab combinations and methodsNANTCELL INC·Filed 2022·Granted Jan 20, 2026·0 cites·14 claims
- 3076US12297247B2Fusion molecules of CTLA4 and IL-15NANTCELL INC·Filed 2023·Granted May 13, 2025·0 cites·12 claims
- 3175US11684668B2Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequenceNANTCELL INC·Filed 2020·Granted Jun 27, 2023·0 cites·16 claims
- 3275US11439697B2Nant cancer vaccineNANTCELL INC·Filed 2021·Granted Sep 13, 2022·0 cites·20 claims
- 3375US2024193784A1Systems And Methods For Performing Segmentation Based On Tensor InputsNANTCELL INC·Filed 2024·Application pending·0 cites
- 3474US11564980B2Tumor treatment method with an individualized peptide vaccineNANTCELL INC·Filed 2019·Granted Jan 31, 2023·1 cites·13 claims
- 3572US2023145817A1Neoepitope vaccine and immune stimulant combinations and methodsNANTCELL INC·Filed 2023·Application pending·0 cites
- 3670US2024354026A1Object Storage And Access Management Systems And MethodsNANTCELL INC·Filed 2024·Application pending·0 cites
- 3769US12571003B2Electroporation with active compensationNANTCELL INC·Filed 2024·Granted Mar 10, 2026·0 cites·5 claims
- 3868US11510982B2HaNK cetuximab combinations and methodsNANTCELL INC·Filed 2018·Granted Nov 29, 2022·0 cites·12 claims
- 3967US11573230B2Rapid verification of virus particle production for a personalized vaccineNANTCELL INC·Filed 2019·Granted Feb 7, 2023·0 cites·12 claims
- 4065US2022257649A1Combination therapies for multiple myelomaNANTCELL INC·Filed 2019·Application pending·0 cites
- 4164US11318189B1IL-15 agonist drug combinations for immune therapyNANTCELL INC·Filed 2021·Granted May 3, 2022·0 cites·26 claims
- 4263US12224064B2Deep learning models for tumor evaluationNANTCELL INC·Filed 2021·Granted Feb 11, 2025·0 cites·16 claims
- 4362US12531134B2HLA clusters, global frequencies, and binding across SARS-CoV-2 variationNANTCELL INC·Filed 2022·Granted Jan 20, 2026·0 cites·30 claims
- 4462US2025230211A1Fusion Molecules Of CTLA4 And IL-15NANTCELL INC·Filed 2025·Application pending·0 cites
- 4562US2023034802A1Nant Cancer VaccineNANTCELL INC·Filed 2022·Application pending·0 cites
- 4661US11941813B2Systems and methods for performing segmentation based on tensor inputsNANTCELL INC·Filed 2020·Granted Mar 26, 2024·0 cites·19 claims
- 4760US2025161412A1Combination therapies for multiple myelomaNANTCELL INC·Filed 2025·Application pending·0 cites
- 4860US2024327492A1Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And CancerNANTCELL INC·Filed 2022·Application pending·0 cites
- 4960US2023218743A1Peptide Therapeutics Against SARS-COV-2 Spike ProteinNANTCELL INC·Filed 2022·Application pending·0 cites
- 5058US2022056542A1Rapid Viral Diagnostic TestNANTCELL INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →